AI Article Synopsis
- Diffuse large B cell lymphoma (DLBCL) is a common blood cancer known for its significant genetic and clinical diversity, making it challenging to understand the disease and treat it effectively.
- Researchers conducted a comprehensive study involving genetic sequencing of 1,001 DLBCL patients to identify 150 key genetic factors contributing to the disease.
- The study developed a prognostic model based on these genetic alterations, which performed better than existing methods, highlighting potential new treatment strategies for DLBCL.
Article Abstract
Diffuse large B cell lymphoma (DLBCL) is the most common form of blood cancer and is characterized by a striking degree of genetic and clinical heterogeneity. This heterogeneity poses a major barrier to understanding the genetic basis of the disease and its response to therapy. Here, we performed an integrative analysis of whole-exome sequencing and transcriptome sequencing in a cohort of 1,001 DLBCL patients to comprehensively define the landscape of 150 genetic drivers of the disease. We characterized the functional impact of these genes using an unbiased CRISPR screen of DLBCL cell lines to define oncogenes that promote cell growth. A prognostic model comprising these genetic alterations outperformed current established methods: cell of origin, the International Prognostic Index comprising clinical variables, and dual MYC and BCL2 expression. These results comprehensively define the genetic drivers and their functional roles in DLBCL to identify new therapeutic opportunities in the disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5659841 | PMC |
| http://dx.doi.org/10.1016/j.cell.2017.09.027 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!